Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Abstract Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A rec...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0622-4 |
id |
doaj-ad5d70f5027a4029a58b49c352f00170 |
---|---|
record_format |
Article |
spelling |
doaj-ad5d70f5027a4029a58b49c352f001702020-11-24T20:40:21ZengBMCJournal of Hematology & Oncology1756-87222018-06-011111510.1186/s13045-018-0622-4Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancersYu Chen0Ping Chi1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterAbstract Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent “basket” study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing “tumor-agnostic” targeted therapies in rare tumors.http://link.springer.com/article/10.1186/s13045-018-0622-4 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yu Chen Ping Chi |
spellingShingle |
Yu Chen Ping Chi Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers Journal of Hematology & Oncology |
author_facet |
Yu Chen Ping Chi |
author_sort |
Yu Chen |
title |
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers |
title_short |
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers |
title_full |
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers |
title_fullStr |
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers |
title_full_unstemmed |
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers |
title_sort |
basket trial of trk inhibitors demonstrates efficacy in trk fusion-positive cancers |
publisher |
BMC |
series |
Journal of Hematology & Oncology |
issn |
1756-8722 |
publishDate |
2018-06-01 |
description |
Abstract Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent “basket” study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing “tumor-agnostic” targeted therapies in rare tumors. |
url |
http://link.springer.com/article/10.1186/s13045-018-0622-4 |
work_keys_str_mv |
AT yuchen baskettrialoftrkinhibitorsdemonstratesefficacyintrkfusionpositivecancers AT pingchi baskettrialoftrkinhibitorsdemonstratesefficacyintrkfusionpositivecancers |
_version_ |
1716827221662892032 |